Personal Genome Diagnostics, Inc. announced that it has received $75 million in funding from New Enterprise Associates, Bristol-Myers Squibb Company, Maryland Department of Business and Economic Development, Endowment Arm, Windham Venture Partners, Inova Strategic Investments, Helsinn Group, Investment Arm, and other investors

On January 4, 2018, Personal Genome Diagnostics, Inc. closed the transaction. The company raised aggregate proceeds of $75,000,000 in its series B round of funding. The round included participation from new investor Bristol-Myers Squibb Company, along with existing investors New Enterprise Associates, Windham Venture Partners Fund, a fund managed by Windham Venture Partners, with other new and existing investors including Maryland Venture Fund L.P. a fund managed by, Maryland Department of Business and Economic Development, Endowment Arm for $2,000,000, Inova Strategic Investments, Helsinn Investment Fund SA, Helsinn Group, Investment Arm, and other undisclosed investors.

The round was led by New Enterprise Associates and Bristol-Myers Squibb Company.